A meta-analysis evaluated liver function and structure in patients with type 2 diabetes, comparing the effects of SGLT2 inhibitors with those of placebo or other oral hypoglycemic agents. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.